GlassScriptPhysician profile
Paul C Lee
NPI 1003838012
$3,010.72
in general payments reported to CMS, 2019-2025
11 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.27 · 2020: $25.14 · 2021: $279 · 2022: $537 · 2023: $702 · 2024: $956 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $960.54 | 2022-2025 | Visumax, Iolmaster 700 |
| Alcon Vision LLC | $781.77 | 2021-2025 | Clareon, Rocklatan, Luxor |
| Sun Pharmaceutical Industries INC. | $412.38 | 2019-2023 | Cequa |
| Rxsight INC | $314.52 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Glaukos Corporation | $188.86 | 2023 | |
| Aerie Pharmaceuticals, INC. | $139.45 | 2020-2021 | |
| Abbott Laboratories | $135.70 | 2024 | Navitor |
| Allergan, INC. | $24.50 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $21.93 | 2019 | |
| Thea Pharma INC. | $16.18 | 2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $14.89 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.